Breast MRI for Assessing Triple-Negative Breast Cancer after Neoadjuvant Chemoimmunotherapy.
作者信息
Onishi Natsuko
机构信息
Department of Radiology & Biomedical Imaging, University of California, San Francisco, 550 16th St, San Francisco, CA 94158.
出版信息
Radiology. 2025 Jul;316(1):e251503. doi: 10.1148/radiol.251503.
Abstract
摘要
相似文献
1
Breast MRI for Assessing Triple-Negative Breast Cancer after Neoadjuvant Chemoimmunotherapy.
Radiology. 2025 Jul;316(1):e251503. doi: 10.1148/radiol.251503.
2
Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis.
Cells. 2022 Jun 7;11(12):1857. doi: 10.3390/cells11121857.
3
Why combine and why neoadjuvant? Tumor immunological perspectives on chemoimmunotherapy in triple-negative breast cancer.
Breast Cancer. 2025 May 6. doi: 10.1007/s12282-025-01707-5.
4
Baseline and Early Treatment MRI Model for Predicting Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy in Patients With Triple-Negative Breast Cancer.
AJR Am J Roentgenol. 2025 Jul 30. doi: 10.2214/AJR.25.33178.
5
Posttreatment MRI to Predict Pathologic Complete Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy.
Radiology. 2025 Jul;316(1):e243824. doi: 10.1148/radiol.243824.
6
Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis.
ESMO Open. 2023 Dec;8(6):102198. doi: 10.1016/j.esmoop.2023.102198. Epub 2023 Dec 14.
7
Diagnostic performance of MRI for assessing axillary lymph node status after neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
Eur Radiol. 2024 Feb;34(2):930-942. doi: 10.1007/s00330-023-10155-8. Epub 2023 Aug 24.
8
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.
JAMA Oncol. 2024 Feb 1;10(2):227-235. doi: 10.1001/jamaoncol.2023.5033.
9
Correlation Between Pathological and MRI Radiological Tumor Responses to Neoadjuvant Chemotherapy in Non-Luminal Breast Cancer: A Single Institution Experience.
Cancer Rep (Hoboken). 2025 Jul;8(7):e70275. doi: 10.1002/cnr2.70275.
10
Intratumoral microbiota-aided fusion radiomics model for predicting tumor response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer.
J Transl Med. 2025 Mar 20;23(1):352. doi: 10.1186/s12967-025-06369-7.
本文引用的文献
1
Posttreatment MRI to Predict Pathologic Complete Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy.
Radiology. 2025 Jul;316(1):e243824. doi: 10.1148/radiol.243824.
2
Emerging and Evolving Concepts in Cancer Immunotherapy Imaging.
Radiology. 2023 Jan;306(1):32-46. doi: 10.1148/radiol.210518. Epub 2022 Dec 6.
3
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2022 Dec;23(12):1517-1524. doi: 10.1016/S1470-2045(22)00613-1. Epub 2022 Oct 25.
4
MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis.
NPJ Breast Cancer. 2022 Sep 19;8(1):107. doi: 10.1038/s41523-022-00475-1.
5
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11.
6
Personalization of Treatment is the Way Forward in Care and Trials.
Clin Cancer Res. 2020 Jun 15;26(12):2771-2773. doi: 10.1158/1078-0432.CCR-20-0604. Epub 2020 Apr 7.
7
Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
8
Imaging Neoadjuvant Therapy Response in Breast Cancer.
Radiology. 2017 Nov;285(2):358-375. doi: 10.1148/radiol.2017170180.
9
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
J Clin Oncol. 2017 Apr 1;35(10):1049-1060. doi: 10.1200/JCO.2015.63.1010. Epub 2017 Jan 30.
10
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.
J Clin Oncol. 2011 Feb 20;29(6):660-6. doi: 10.1200/JCO.2010.31.1258. Epub 2011 Jan 10.
Zotero 插件